Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$161.28M+18.10%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Virnich
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 641
- Beta
- 0.44
- Country
- US
Financials
STLN has only 4 quarterly periods on file — the charts below show the full history available.
Revenue
$161.28M+18.1%Net Income
$-9.79MEBITDA
$-6.09MFree Cash Flow
$11.03MEPS (diluted)
$-0.08Shares Outstanding (diluted)
103.03M+5.7%Operating Expenses
$29.94MCash & Debt
$41.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $502.73M | $-60.61M | $-0.54 |
Valuation
STLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·4d ago·Neutral
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating Starling Oncology is rated BUY, supported by strong secular growth and expanding adoption of its oncology managed care services. STLN's revenue model leverages scalable delegation contracts, driving higher PMPM fees, pharmacy growth, and gross profit expansion. FY26 guidance was raised: revenue is up 31%, gross profit is up 41%, and positive EBITDA ($2–$7M) and free cash flow ($10M) are expected.
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
Starling Oncology to Participate in Wells Fargo Healthcare Conference CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a f…
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
… Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care's persistent challenges: NCCN compliance by the medical community and a fragmented and administr…
View source ↗
Earnings
Typical surprise -25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.08 vs $-0.06miss
- Thu, May 7$-0.02 vs $-0.09beat
- Wed, Aug 13$-0.15 vs $-0.12miss
- Tue, Aug 13$-0.17 vs $-0.09miss
Estimates and results for STLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by STLN officers and directors.
- Bought
- $78k
- Sold
- $1.9m
1 trade
2 trades
- Hively Bradsold
- Chernett Joreybought
- Chernett Joreysold
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in STLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.